Bio-Techne Corp (TECH)
Working capital turnover
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 1,219,634 | 1,208,768 | 1,196,015 | 1,171,582 | 1,159,059 | 1,154,281 | 1,144,999 | 1,143,982 | 1,136,702 | 1,123,611 | 1,119,841 | 1,117,536 | 1,105,600 | 1,076,399 | 1,029,575 | 984,552 | 931,032 | 847,838 | 798,966 | 759,647 |
Total current assets | US$ in thousands | 608,300 | 627,240 | 634,640 | 648,567 | 617,419 | 610,650 | 590,640 | 591,477 | 621,482 | 570,996 | 565,183 | 552,031 | 605,556 | 593,108 | 590,230 | 543,748 | 510,606 | 566,606 | 541,933 | 541,893 |
Total current liabilities | US$ in thousands | 175,849 | 169,204 | 161,256 | 142,128 | 159,379 | 149,820 | 135,231 | 127,754 | 128,509 | 141,163 | 128,395 | 137,629 | 176,018 | 166,838 | 154,809 | 133,992 | 152,284 | 137,640 | 117,568 | 105,424 |
Working capital turnover | 2.82 | 2.64 | 2.53 | 2.31 | 2.53 | 2.50 | 2.51 | 2.47 | 2.31 | 2.61 | 2.56 | 2.70 | 2.57 | 2.53 | 2.36 | 2.40 | 2.60 | 1.98 | 1.88 | 1.74 |
June 30, 2025 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $1,219,634K ÷ ($608,300K – $175,849K)
= 2.82
The analysis of Bio-Techne Corp's working capital turnover ratio from September 30, 2020, to June 30, 2025, reveals a pattern of gradual fluctuations with periods of increase and slight declines. Initially, the ratio increased from 1.74 in September 2020 to 2.60 by June 2021, indicating an improvement in the efficiency of utilizing working capital to generate sales during this period. Subsequently, the ratio experienced minor oscillations, reaching approximately 2.70 in September 2022 before stabilizing around 2.50 to 2.60 in the subsequent quarters.
Throughout the period, the ratio generally remained above 2.3, suggesting a relatively consistent efficiency in working capital utilization. The peak value observed was approximately 2.82 in June 2025, while the lowest was 1.74 in September 2020. The ratios display a pattern of expansion followed by slight contraction, which may reflect adjustments in operational efficiency or changes in working capital management strategies.
Overall, the data suggests that Bio-Techne Corp has maintained a steady level of operational efficiency in managing its working capital relative to sales. The modest fluctuations are typical of a stable company, with a trend towards marginal improvement in recent periods, as evidenced by the ratio surpassing 2.5 in the latest measurements.
Peer comparison
Jun 30, 2025